文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

利福平联合克拉霉素(缓释)与利福平联合链霉素治疗局限性布鲁里溃疡的随机开放标签非劣效3期试验

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
PubMed 文献 · Lancet · 2020-03-12

本研究为开放标签、非劣效、多中心3期随机试验,比较全口服利福平联合克拉霉素缓释片(RC8)与利福平联合链霉素(RS8)治疗早期局限性布鲁里溃疡的疗效与耐受性。结果显示RC8在52周病灶愈合率上非劣效于RS8,且不良事件更少,作者建议全口服RC8作为早期局限性布鲁里溃疡的首选治疗。

要点

  • 全口服RC8方案在52周病灶愈合率上非劣效于RS8方案。
  • RC8组治疗相关不良事件发生率低于RS8组,无严重耳毒性报告。
  • RC8可作为早期局限性布鲁里溃疡的首选治疗方案。

核心结论

  • 全口服RC8方案治疗早期局限性布鲁里溃疡在病灶愈合方面非劣效于RS8方案,且不良事件更少,建议作为首选治疗。

研究设计与样本

  • 开放标签、非劣效、多中心3期随机对照试验,1:1区组随机(区组大小6),在加纳4个中心和贝宁1个中心开展。
  • 纳入年龄≥5岁、典型布鲁里溃疡且病灶数不超过1个(类别I和II)、直径不超过10 cm的患者。
  • 主要终点为抗菌治疗开始后52周时病灶愈合(完全上皮化或稳定瘢痕)且无复发,在意向治疗人群中评估主要终点和安全性。
  • 计划样本量332例,以12%的非劣效界值检测RC8的非劣效性;实际招募310例后停止招募。

主要发现

  • RS8组151例中144例(95%,95%CI 91-98)病灶愈合,RC8组146例中140例(96%,95%CI 91-99)病灶愈合。
  • 治疗相关不良事件在RS8组20例(13%)和RC8组9例(7%)中记录,多数为1-2级。
  • RS8组1例(1%)发生严重耳毒性并在6周后终止治疗;无患者需要手术切除,两组各2例接受皮肤移植。

关键数值与推荐

  • RS8组愈合率95%(95%CI 91-98),RC8组96%(95%CI 91-99)。

临床怎么用

  • 对于早期、局限性布鲁里溃疡(类别I和II,病灶直径≤10 cm),可优先选用全口服RC8方案。
  • RC8方案为利福平10 mg/kg联合克拉霉素缓释片15 mg/kg每日一次,疗程8周。

局限性

  • 开放标签设计,测量病灶的研究者和主治医生未设盲。
  • 实际招募310例,未达到计划样本量332例。
  • 研究仅纳入早期局限性病灶(≤10 cm,类别I和II),结论不能外推至晚期或更大病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8) is highly effective, but streptomycin injections are painful and potentially harmful. We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8) with that of RS8 for treatment of early Buruli ulcer lesions. METHODS: We did an open-label, non-inferiority, randomised (1:1 with blocks of six), multicentre, phase 3 clinical trial comparing fully oral RC8 with RS8 in patients with early, limited Buruli ulcer lesions. There were four trial sites in hospitals in Ghana (Agogo, Tepa, Nkawie, Dunkwa) and one in Benin (Pobè). Participants were included if they were aged 5 years or older and had typical Buruli ulcer with no more than one lesion (caterories I and II) no larger than 10 cm in diameter. The trial was open label, and neither the investigators who took measurements of the lesions nor the attending doctors were masked to treatment assignment. The primary clinical endpoint was lesion healing (ie, full epithelialisation or stable scar) without recurrence at 52 weeks after start of antimicrobial therapy. The primary endpoint and safety were assessed in the intention-to-treat population. A sample size of 332 participants was calculated to detect inferiority of RC8 by a margin of 12%. This study was registered with ClinicalTrials.gov, NCT01659437. FINDINGS: Between Jan 1, 2013, and Dec 31, 2017, participants were recruited to the trial. We stopped recruitment after 310 participants. Median age of participants was 14 years (IQR 10-29) and 153 (52%) were female. 297 patients had PCR-confirmed Buruli ulcer; 151 (51%) were assigned to RS8 treatment, and 146 (49%) received oral RC8 treatment. In the RS8 group, lesions healed in 144 (95%, 95% CI 91 to 98) of 151 patients, whereas lesions healed in 140 (96%, 91 to 99) of 146 patients in the RC8 group. The difference in proportion, -0·5% (-5·2 to 4·2), was not significantly greater than zero (p=0·59), showing that RC8 treatment is non-inferior to RS8 treatment for lesion healing at 52 weeks. Treatment-related adverse events were recorded in 20 (13%) patients receiving RS8 and in nine (7%) patients receiving RC8. Most adverse events were grade 1-2, but one (1%) patient receiving RS8 developed serious ototoxicity and ended treatment after 6 weeks. No patients needed surgical resection. Four patients (two in each study group) had skin grafts. INTERPRETATION: Fully oral RC8 regimen was non-inferior to RS8 for treatment of early, limited Buruli ulcer and was associated with fewer adverse events. Therefore, we propose that fully oral RC8 should be the preferred therapy for early, limited lesions of Buruli ulcer. FUNDING: WHO with additional support from MAP International, American Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, Sanofi-Pasteur, and BuruliVac.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Phillips RO, Robert J, Abass KM, et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet. 2020. PMID: 32171422. doi:10.1016/S0140-6736(20)30047-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。